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CTVprostate+3mm D90 was in accordance with institutional 
constraints (95% of prescribed dose) in 74 of 81 procedures. 
Insufficient coverage was caused by suboptimal needle 
implant (5 procedures) and catheter migration (2 
procedures). CTVprostate+3mm D90 was significantly improved 
over time, and tended to be better at the second HDR BT. 
Urethral dose D0.1cc constraints was fulfilled (<=10 Gy) in 65 
of 81 procedures. Rectal dose D2cc constraint was fulfilled 
(<6.4 Gy) in 79 of 81 procedures. Increased CTVprostate+3mm D90 
was not related with increased urethral or rectal dose. 
Conclusions: After introduction of MRI guided HDR BT, 
implant time and total procedure time was reduced to ~2.5 
hours and ~5 hours, respectively. Post implant MRI prolonged 
the HDR BT procedure by an estimated median of 66 min. 
Dose to CTVprostate+3mm mostly fulfilled institutional constraints 
and was improved over time, but not at the expense of an 
increased urethral or rectal dose.  
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Purpose/Objective: The aim of the present prospective study 
is to analyze short and intermediate-term outcomes and 
toxicity after salvage brachytherapy (BT) with I-125 for local 
failure after BT or external beam radiotherapy (EBRT) for 
prostate cancer. 
Materials and Methods: From January 2010 and September 
2014, 24 patients with PSA relapse (Phoenix definition for 
those with previous androgen deprivation (AD) and ASTRO 
definition for the rest), and histological confirmation with 
template-guided biopsy, underwent salvage BT with I-125 at 
least 2 years after the initial treatment (15 BT and 9 EBRT). 
Magnetic resonance imaging (MRI) and/or PET-CT as study of 
distant disease were realized in every case. At relapse, 
average age was 71 years (58-82), median Gleason was 7 and 
PSA pre-salvage BT 5.65 ng/ml (2.81-11.7). Two patients 
were treated with androgen deprivation therapy (ADT) 
previously salvage BT. The median dose to 90% of prostate 
volume was 129.1 Gy (84.18-151.47) with a median seed 
activity of 0.506 mCi (0.319-0.518). Constraint median doses 
for urethra and rectum were 162 Gy and 120 Gy, 
respectively. Every case required post-planning with post 
implant-CT. Post implant-MRI was realized in-patient without 
history of brachytherapy with iodine-125 radiation seeds. 
Toxicities were graded using CTCv4.0. 
Results: With a median follow up of 39 months (2-55): 19 
(79%) patients are free from biochemical failure, 3 patients 
have developed PSA relapse with distant failure evidence, 2 
patients presented PSA relapse within the first 6-12 months 
after salvage brachytherapy. The toxicities found 
corresponding to: one case grade 3 (TURP after acute urine 
retention) and two cases grade 2 (acute rectal mucositis and 
acute cystitis in the same patient). 
Conclusions: Despite of the short follow-up in some patients, 
BT seems to be a safe and effective treatment option for 
salvage treatment, but careful patient selection is essential 
to improve outcomes. 
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Purpose/Objective: Stereotactic Ablative Radiotherapy 
(SABR) is increasing in popularity in several tumour sites 
including prostate cancer. A pilot study of low to 
intermediate risk Prostate cancer patients treated using 
Volumetric Arc Therapy (VMAT) and Flattening Filter Free 
(FFF) beams is ongoing at our institution. Initial toxicity data 
are presented in this report. 
Materials and Methods: Key inclusion criteria in the study 
was patients with low to intermediate risk, localised Prostate 
cancer. Staging was performed using MRI in all patients and a 
bone scan in selected cases. Planning CT and MRI were 
obtained on the same day, with bladder and bowel 
preparation. MRI and CT planning scans were fused and, 
following this, prostate, seminal vesicles and organs at risk 
were outlined by a consultant Clinical Oncologist. VMAT plans 
were produced utilising 10X FFF beams RapidArc 10.028 and 
AAA 10.0.2.28 algorithms. Patients were treated on a Varian 
TrueBeam STx Linear Accelerator at a dose of 35Gy/5 
fractions delivered on alternate days. Cone Beam CT was 
used before each treatment to verify treatment position 
using fiducial marker (gold seed) and soft tissue matching. 
Toxicity was assessed using RTOG toxicity grading prior to 
each fraction of radiotherapy and then at week 4, 10, 18 and 
6 months.  
Results: To date, 22 patients have been enrolled into the 
study. Median age is 70 years, range 52-78yrs. All patients 
have clinical and radiological stage T1-2 disease. Median iPSA 
was 10.65, range 4-29.2 µg/l. 
We have toxicity data on 17 patients who have so far 
completed at least 10 weeks follow up, assessed using RTOG 
acute toxicity scoring. 
 Genitourinary toxicity;  
o 9 patients (53%) had grade 1 symptoms at 
baseline  
o 6 patients (35%) developed grade 2 
toxicity; resolved to grade 1 by week 18 
in all patients (1 not yet reached week 18 
follow-up)  
 
 Gastrointestinal toxicity  
o 2 patients (12%) developed grade 2 
toxicity; both resolved to grade 1, 1 
patient by week 18 and the second 
patient by week 24.  
 
No patient experienced any Grade 3 or 4 toxicity. 
Conclusions: These preliminary data show that treating low 
to intermediate risk prostate cancer patients with SABR using 
VMAT and FFF is safe and deliverable in a busy Tertiary Care 
referral centre with mild, acute GI and GU toxicity. Long 
